SRC and neoplasm: Taken together, our results demonstrate that simultaneous blockade of JAK/STAT3, PI3K/AKT/mTOR, SRC and MEK/MAPK pathways results in better anti-tumor activity compared to inhibiting any one or two or three of these signaling pathways.